Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK announces changes to the Board
GSK announced at annual GM in 2013,that Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board.
-
GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina
GSK respectfully disagrees with court ruling in favour of ANMAT on fine issued regarding conduct of the COMPAS study in Mendoza, Argentina
-
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma
GSK & THRX announced completion of phase III registration programme for Relovair in patients with COPD and in patients with asthma.
-
GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands
Agreement reached to divest brands in USA and Canada to Prestige Brands Holdings, Inc. for £426m ($660m).
-
GSK extends pneumococcal vaccine agreement with GAVI Alliance
GSK & GAVI to help protect millions more children in the world's poorest countries from pneumococcal disease.
-
GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus
GSK & HGS announced dosing has been initiated in BLISS-SC, a new Phase III study of belimumab administered SC to adults with SLE.
-
GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium
Improvement in disease-free survival does not reach statistical significance in study of Tykerb monotherapy in HER2 positive breast cancer.
-
GSK and Help for Heroes partner to support the rehabilitation of wounded servicemen and women in the UK
GSK & Help for Heroes announced new partnership to help injured British armed forces personnel successfully transition into civilian life.
-
GSK statement in response to the Prime Minister’s speech on life sciences
The Government's strategy for Life Sciences is an important step to make UK the best place in the world to locate pharmaceutical investment.
-
Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine
GSK submitted information to the FDA supporting BLA for combination vaccine MenHibrix. submitted in response to Complete Response letter.
-
Reporting on a core earnings basis will begin with effect from Q1 2012
Go to the Presentations and webcasts page for the full announcement.
-
GSK welcomes GAVI Alliance decision to introduce vaccines against cervical cancer and rubella in the world’s poorest countries
GAVI Board to provide funding for cervical cancer immunisation programmes & rubella vaccination, across the world's poorest countries.
-
GlaxoSmithKline welcomes innovative knowledge-sharing collaboration to break deadlock in antibiotic discovery and development
GSK welcomes EC decision to promote collaborative research efforts to develop new antibiotics against growing threat from resistant bacteria
-
GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes
Head-to-head study primary end point did not meet non-inferiority, but results support progression towards registration
-
Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix® (HPV 16 and 18 vaccine) against precancerous cervical lesions
Analysis in TheLancet reinforces findings that GSK's Cervarix, provided protection against CIN3+, above expected from a vaccine against HPV.
-
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia
Full results from ENABLE 1 & 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases
-
GlaxoSmithKline reaches agreement in principle to resolve multiple investigations with US Government
GSK announced it's reached an agreement with US Gov to conclude the Company’s most significant ongoing Federal government investigations
-
GSK delivers strong Q3 performance with underlying sales growth of 6% and reported sales growth of 3%
Full details of GSK's results for the third quarter of 2011 can be found in the Investors section of GSK.com.
-
GSK joins WIPO Re:Search open innovation platform as part of its commitment to tackling diseases of the developing world
GSK joined WIPO Re:Search in innovation strategy to help accelerate the development of treatments of NTDs affecting over a billion each year
-
First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months
Half the world's population at risk of malaria responsible for 800,000 deaths each year, most of whom children under 5 in sub-Saharan Africa
